Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ZIVO Bioscience filings document a biotech and agtech research and development company with common stock and warrants and an intellectual property portfolio covering proprietary algal and bacterial strains, biologically active molecules and complexes, cultivation techniques, production techniques, and patented or patent-pending inventions for human and animal health.
Recent Form 8-K disclosures address corporate-status matters involving SEC reporting obligations and OTC market securities, Board determinations, executive finance leadership changes, separation agreements, compensatory arrangements, and other material events tied to ZIVO's public-company governance and capital structure.
Zivo Bioscience, Inc. reported that an entity associated with 10% owner Mark E. Strome acquired additional common stock. On April 17, 2026, Strome Mezzanine Fund II, LP purchased 100,000 shares of Zivo common stock at $2.00 per share.
Following this transaction, the reporting group’s indirect holdings rose to 572,942 shares of common stock. The filing notes that the reporting persons may be deemed to share voting and investment power over these shares, while also disclaiming beneficial ownership for certain legal purposes.
ZIVO Bioscience, Inc. plans to voluntarily delist its common stock and warrants from the OTC markets and file a Form 15 to deregister its securities and suspend SEC reporting obligations on or around March 30, 2026. The board concluded that the legal, accounting, and administrative costs of SEC compliance place a significant financial burden on the company and divert resources from its core biotech and agtech R&D operations. Once Form 15 is filed, ZIVO’s obligations to file Forms 10-K, 10-Q, and 8-K will immediately cease. Management states it will continue focusing on animal health and nutrition initiatives, aiming to redirect savings from public-company compliance toward advancing its strategic plan and long-term stockholder value.
Zivo Bioscience director and 10% owner–associated entity buys shares. An entity associated with director and ten percent owner Laith L. Yaldoo, identified as HEP Investment, LLC, made an open-market purchase of 1,543 shares of Zivo Bioscience common stock at $9.72 per share. After this transaction, the filing reports 583,615 shares of common stock indirectly owned.
Strome-affiliated investors updated their ownership in Zivo Bioscience’s common stock. Mark E. Strome now reports beneficial ownership of 472,942 shares, or 12.10% of the company’s 3,888,595 shares outstanding as of November 9, 2025.
Strome Mezzanine Fund II holds 266,198 shares, representing 6.81% of the company, after merging with Strome Mezzanine Fund on December 31, 2025 and becoming the surviving entity. SMF ceased to hold any shares following this merger.
On February 12, 2026, Strome Mezzanine Fund II acquired 20,000 shares of Zivo Bioscience at $9.77 per share under a Securities Purchase Agreement and received a warrant, for no additional consideration, exercisable for 2,000 additional shares at $9.77 per share, subject to adjustments.
Zivo Bioscience reported that investment entities associated with 10% owner Mark E. Strome, through Strome Mezzanine Fund II, LP, bought 20,000 shares of common stock at $9.77 per share and 2,000 common stock purchase warrants on February 12, 2026.
After these indirect purchases, the entities reported beneficial ownership of 472,942 common shares and 45,071 warrants.
Zivo Bioscience insider reporting shows an indirect open-market purchase of common stock tied to director and 10% owner Laith L. Yaldoo. On 02/10/2026, HEP Investments LLC, an entity associated with Yaldoo, bought 2,434 shares of Zivo Bioscience common stock at $10.27 per share. Following this transaction, HEP Investments LLC indirectly held 582,072 shares of common stock.
Zivo Bioscience director Alison Cornell reported buying additional company stock. On January 26, 2026, she purchased 11,709 shares of common stock at a price of $8.54 per share. Following this transaction, she directly beneficially owns 279,481 shares of Zivo Bioscience common stock.
Zivo Bioscience, Inc. President and CEO John B. Payne reported an open-market purchase of company stock. On 01/26/2026, he bought 11,709 shares of common stock at $8.54 per share. Following this transaction, he directly owns 19,618 shares of Zivo Bioscience common stock.